



Aravive to Report Fourth Quarter and Full Year 2018 Financial Results and Corporate Updates on March 7, 2019

February 28, 2019

HOUSTON, Feb. 28, 2019 (GLOBE NEWSWIRE) -- Aravive, Inc. (Nasdaq: ARAV), a clinical-stage biopharmaceutical company, announced the company plans to report financial results for the fourth quarter and full year 2018 and provide corporate updates on March 7, 2019 after the close of the U.S. financial markets.

To receive Aravive's press releases and other investor information, please visit the [Investor Relations page](#) of the company's website and register for [email alerts](#).

About Aravive

Aravive, Inc. (Nasdaq: ARAV) is a clinical stage biopharmaceutical company focused on developing innovative therapies that target important survival pathways for cancer. Aravive's lead candidate, AVB-S6-500, is a novel, high-affinity, soluble Fc-fusion protein designed to block the activation of the GAS6-AXL signaling pathway by intercepting the binding of GAS6 to its receptor AXL. AXL receptor signaling plays an important role in multiple types of malignancies by promoting metastasis, cancer cell survival, resistance to treatments, and immune suppression. Aravive has initiated the phase 1b portion of a phase 1b/2 clinical trial of AVB-S6-500 combined with standard of care therapies in patients with platinum-resistant recurrent ovarian cancer, and intends to expand development into additional oncology and fibrotic indications. For more information, please visit www.aravive.com.

Contacts:

Investors:

Mike Zanoni
Endurance Advisors
mzanoni@enduranceadvisors.com
610-442-8570

Media:

Jordann Phillips
Canale Communications
jordann@canalecomm.com
619-849-6009



Source: Aravive, Inc.